Medarva Innovations

TearSolutions, Inc. is a biotechnology company based in Charlottesville, Virginia, focused on developing innovative therapies for dry eye conditions. Founded in 2013, the company is advancing Lacripep, a synthetic peptide derived from the natural tear protein lacritin, aimed at treating dry eyes, particularly in patients with primary Sjögren's syndrome. Lacripep is designed to preserve the biological activity of natural tear components while promoting healing of the corneal surface and alleviating symptoms without irritation. Currently, the company is conducting phase II human clinical trials to further validate its approach. TearSolutions employs an outsourcing model for its operations, emphasizing efficiency and scalability in the development and production of its therapies.